You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 110 No. 6, Dec 1962 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (55)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Radioiodine in Diagnosis and Therapy of Hyperthyroidism

Hyperthyroidism Caused by Hyperfunctioning Thyroid Adenoma

PENN G. SKILLERN, M.D.; E. PERRY McCULLAGH, M.D.; MARVIN CLAMEN, M.D.

Arch Intern Med. 1962;110(6):888-897.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The occurrence of hyperthyroidism particularly in the older patient with a nodular goiter has resulted in the publication of numerous papers on the radioiodine treatment of "toxic nodular goiter." The term "toxic nodular goiter" as used by the authors of these published reports recently reviewed by Eller and associates1 implies that the hyperthyroidism is caused by a hyperfunctioning nodule or nodules in the goiter. In reality however, careful perusal of many of these reports reveals that a variable number of patients with Graves' disease have been included in these series. In such patients it is the internodular thyroid tissue which undergoes hyperplasia producing the hyperthyroidism, while the nodules are actually non functioning. Clinically, this is further substantiated by the inclusion of patients with exophthalmos1-4 which is specific for Graves' disease. Also, the occurrence of hypothyroidism which has been reported averaging 7%-8% of the patients in 14 of the . . . [Full Text PDF of this Article]


Author Affiliations

CLEVELAND

Member of the Staff, Department of Endocrinology and Metabolism (Dr. Skillern and Dr. Mc-Cullagh).; Formerly Fellow, Department of Endocrinology and Metabolism; present address: 5300 Cote de Neiges Rd., Suite 600, Montreal 26, Canada (Dr. Clamen).; From the Department of Endocrinology and Metabolism, The Cleveland Clinic Foundation. The radioactive material was obtained on authorization of the United States Atomic Energy Commission.


Footnotes

Submitted for publication April 28, 1962, accepted for publication June 1, 1962.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1962 American Medical Association. All Rights Reserved.